Literature DB >> 10888422

Hepatocellular carcinoma.

E K Bergsland1, A P Venook.   

Abstract

Hepatocellular carcinoma (HCC) is a disease that is extremely difficult to manage and is increasing markedly in incidence. This presents both an opportunity and a challenge. At-risk patients can be identified and early detection of HCC is feasible. New surgical techniques and postoperative therapies, including hepatic intra-arterial radiation, may improve the outlook for some patients with resectable cancer. Unfortunately, the vast majority of patients with HCC will have unresectable cancers. Regional treatments may shrink or necrose tumors, but no clear benefit to such therapies has been demonstrated. Recent evidence suggests combination chemotherapy may help some patients, although this needs validation. Perhaps the best hope is that the further elucidation of the genetic and molecular features of HCC will lend us insight into innovative strategies to manage this difficult cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10888422     DOI: 10.1097/00001622-200007000-00013

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  11 in total

1.  Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.

Authors:  Xue-Xi Yang; Jing-Zhe Sun; Fen-Xia Li; Ying-Song Wu; Hong-Yan Du; Wei Zhu; Xiang-Hong Li; Ming Li
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

2.  Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma.

Authors:  Elizabeth M Jablonski; M Adrian Mattocks; Eugene Sokolov; Leonidas G Koniaris; Francis M Hughes; Nelson Fausto; Robert H Pierce; Iain H McKillop
Journal:  Cancer Lett       Date:  2006-11-03       Impact factor: 8.679

3.  Effects of Terminalia arjuna bark extract on apoptosis of human hepatoma cell line HepG2.

Authors:  Sarveswaran Sivalokanathan; Marati Radhakrishnan Vijayababu; Maruthaiveeran Periyasamy Balasubramanian
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

4.  Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin.

Authors:  Gianluigi Giannelli; Emilia Fransvea; Felice Marinosci; Carlo Bergamini; Silvia Colucci; Oronzo Schiraldi; Salvatore Antonaci
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

5.  Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

Authors:  Benjamin Cieply; Gang Zeng; Tracy Proverbs-Singh; David A Geller; Satdarshan P S Monga
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region.

Authors:  Kouji Katabami; Hiromi Mizuno; Rikio Sano; Yuta Saito; Masaharu Ogura; Saotomo Itoh; Tsutomu Tsuji
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

Review 7.  Role of Wnt/β-catenin signaling in liver metabolism and cancer.

Authors:  Satdarshan Pal Singh Monga
Journal:  Int J Biochem Cell Biol       Date:  2009-09-09       Impact factor: 5.085

8.  Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.

Authors:  Ahmed Zidan; Hubert Scheuerlein; Silke Schüle; Utz Settmacher; Falk Rauchfuss
Journal:  Hepat Mon       Date:  2012-10-24       Impact factor: 0.660

9.  Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo.

Authors:  W Jiao; K Miyazaki; Y Kitajima
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

Review 10.  Hepatitis C and hepatocellular carcinoma.

Authors:  F Yao; N Terrault
Journal:  Curr Treat Options Oncol       Date:  2001-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.